Compare SCYX & KPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCYX | KPLT |
|---|---|---|
| Founded | 1999 | 2012 |
| Country | United States | United States |
| Employees | N/A | 87 |
| Industry | Biotechnology: Pharmaceutical Preparations | Diversified Commercial Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.0M | 39.2M |
| IPO Year | 2014 | 2019 |
| Metric | SCYX | KPLT |
|---|---|---|
| Price | $5.14 | $6.92 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | $3.00 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 239.4K | 50.4K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 61.36 | ★ 98.15 |
| EPS | N/A | ★ N/A |
| Revenue | $257,000.00 | ★ $291,761,000.00 |
| Revenue This Year | N/A | $18.62 |
| Revenue Next Year | $608.78 | $15.34 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 18.03 |
| 52 Week Low | $0.57 | $5.50 |
| 52 Week High | $5.62 | $24.15 |
| Indicator | SCYX | KPLT |
|---|---|---|
| Relative Strength Index (RSI) | 62.82 | 56.59 |
| Support Level | $0.65 | $6.07 |
| Resistance Level | $5.58 | $9.23 |
| Average True Range (ATR) | 0.44 | 0.70 |
| MACD | 0.03 | 0.11 |
| Stochastic Oscillator | 85.57 | 49.65 |
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
Katapult Holdings Inc. is a technology-driven lease-to-own platform that integrates with omni-channel retailers and e-commerce platforms to power the purchase of everyday durable goods for underserved U.S. non-prime consumers. It is an e-commerce-focused FinTech company offering a lease-purchase solution to consumers and enabling essential transactions at the merchant point of sale. Katapult is associated with hundreds of retailers across the United States.